Latest news with #GuardantInfinity
Yahoo
29-05-2025
- Health
- Yahoo
Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers
Guardant Health, Inc. (NASDAQ:GH) has introduced major upgrades to its Guardant360 Liquid biopsy test, significantly expanding its cancer biomarker detection and subtyping abilities. Utilizing the Guardant Infinity platform and AI-driven analysis, the test now offers comprehensive multiomic profiling from a simple blood draw. A patient viewing their medical diagnosis on a digital healthcare ecosystem. The enhanced test helps doctors quickly exclude actionable mutations in lung and colorectal cancers, identify cancer origins when unknown, and accurately classify breast and lung cancer subtypes through tumor methylation patterns. It also integrates pharmacogenomic data to guide safe drug use, detects viruses like HPV and EBV affecting treatment, assesses Homologous Recombination Deficiency (HRD) for targeted therapies, and uses HLA genotyping to inform therapy choices and clinical trial options. Guardant Health, Inc. (NASDAQ:GH)'s co-CEO Helmy Eltoukhy highlighted that this blood-based test provides vital tumor insights without needing tissue samples, delivering results within seven days and enabling faster, smarter cancer treatment decisions. While we acknowledge the potential of GH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
25-04-2025
- Business
- Yahoo
Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform
Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the development and commercialization of Pfizer's oncology portfolio using the Guardant Infinity smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfizer aim to: Utilize Guardant's portfolio of liquid biopsy tests in Pfizer's global clinical studies. Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor therapy response and (b) related blood-based epigenomic analyses. Also Read: The collaboration will also allow Pfizer to access Guardant's liquid biopsy tests in China for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with Adicon Holdings Limited, an independent clinical laboratory company based in China, to offer Guardant tests to biopharmaceutical companies conducting clinical trials in China. In January, Guardant Health announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy. Guardant Reveal, which runs on Guardant's Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal residual disease (MRD). This test predicts cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy. Price Action: GH stock is up 2.59% at $46.82 at the last check Thursday. Read Next:Photo by Aunt Spray via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? PFIZER (PFE): Free Stock Analysis Report This article Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
